Date: 2016-06-20
Type of information: Private placement
Company: Spark Therapeutics (USA - PA)
Investors:
Amount: $128.0 million
Funding type: private placement
Planned used:
Others: * On June 20, 2016, Spark Therapeutics announced the closing of its previously announced underwritten public offering of common stock pursuant to an automatically effective shelf registration statement that was previously filed with the Securities and Exchange Commission, including the exercise in full by the underwriters of their option to purchase an additional 525,000 shares from Spark at the public offering price of $45.00 per share, less the underwriting discount. The exercise of the option brought the total number of shares sold in the offering to 4,025,000, consisting of 3,025,000 shares sold by Spark and 1,000,000 shares sold by The Children’s Hospital of Philadelphia Foundation, and increased the aggregate net proceeds to Spark to approximately $128.0 million, after deducting underwriting discounts and before offering expenses. Spark did not receive any proceeds from the sale of shares by CHOP. * On June 14, 2016, Spark Therapeutics announced the pricing of an underwritten public offering of 3,500,000 shares of its common stock pursuant to an automatically effective shelf registration statement that was previously filed with the Securities and Exchange Commission at a public offering price of $45.00 per share, before offering discounts. The offering consists of 2,500,000 shares being offered by Spark and 1,000,000 shares being offered by The Children’s Hospital of Philadelphia Foundation (“CHOP”), resulting in aggregate net proceeds of approximately $105.8 million to Spark and approximately $42.3 million to CHOP, after deducting underwriting discounts and before offering expenses. In addition, Spark has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 525,000 shares at the public offering price, less the underwriting discount. Spark will not receive any proceeds from the sale of shares by CHOP. The offering is expected to close on or about June 20, 2016, subject to customary closing conditions. * On June 13, 2016, Spark Therapeutics announced that it has commenced an underwritten public offering of 3,500,000 shares of its common stock pursuant to an automatically effective shelf registration statement that has been filed with the Securities and Exchange Commission. The offering consists of 2,500,000 shares being offered by Spark and 1,000,000 shares being offered by The Children’s Hospital of Philadelphia Foundation. In addition, Spark is expected to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional 525,000 shares at the public offering price, less the underwriting discount. Spark will not receive any proceeds from the sale of shares by the Children’s Hospital of Philadelphia Foundation. J.P. Morgan Securities LLC and Cowen and Company, LLC will act as bookrunning managers for the offering. The offering will be made only by means of a prospectus.
Therapeutic area: Rare diseases - Genetic diseases
